

Shaping stakeholder perspectives on the long-term clinical benefit of immuno-oncologic therapies



SUMMARY

Our client had identified a need to drive consistent messaging and methodological approaches to better demonstrate the long-term benefits of immuno-oncologic (IO) therapies, which HTA agencies tend to underestimate.

OUR APPROACH

Review of HTAs and publications

Current approaches to demonstrating and assessing the long-term survival benefit with IO agents were identified by reviewing 27 publications and 86 HTAs of client and competitor products, summarized in an interactive Excel-based library.

Steering committee

Regular meetings were convened and reviews undertaken by a global, multi-stakeholder steering committee comprising payers, economists, and clinicians, to critically evaluate the existing methodological approaches and identify key challenges. A draft set of guiding principles for demonstrating long-term benefit was developed.

Country panels

Double-blinded multi-stakeholder advisory board meetings were held in France, Germany, Sweden, the UK, and the US to identify the challenges for assessing IO therapies in each country and provide feedback on the guiding principles.

Guiding principles

A final set of key challenges and guidance principles for describing and presenting new methodical practice was developed for the client to use internally.

Two manuscripts and an ISPOR EU 2019 educational symposium were delivered to inform external audiences.



CLIENT VALUE

Systematic evaluation of IO therapies: conceptual checklist and internal framework

- Valuable tools that can be applied to assets in development, to ensure their full value is captured when preparing for HTA.
- Enables internal alignment and ensures consistency in the methodological approach taken.
- Better demonstration and communication of the long-term clinical benefit of IO agents is expected to result in better HTA outcomes.

External communication to a broad audience

- The manuscripts and ISPOR educational symposium, which was highly praised by peers, communicated the principles and methodological approaches to valuing IO therapies, to inform HTA and other stakeholders.
- They also support the client's position as leader in developing IO therapies.